Home Tests in Mind, Doudna Startup Races Rivals in CRISPR Diagnostics – Xconomy
Xconomy |
Home Tests in Mind, Doudna Startup Races Rivals in CRISPR Diagnostics
Xconomy Another name for Cas12 is Cpf1, which Zhang and several others first characterized in a publication in 2015. Months later Editas Medicine (NASDAQ: EDIT), of which Zhang is a cofounder, announced it had licensed exclusive rights to use CRISPR–Cpf1 for … A New Startup Wants to Use Crispr to Diagnose Disease |
